<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Legislation</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Nearly 30% of trials not up to date on results disclosures </title>
      <description>
        <![CDATA[The U.S. FDA sent out a friendly reminder to more than 2,200 sponsors and researchers, associated with more than 3,000 clinical trials, who may be delinquent in disclosing the results of those studies on clinicaltrials.gov.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730299</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730299-nearly-30-of-trials-not-up-to-date-on-results-disclosures</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Clinical-data-illustration.webp?t=1621541773" type="image/png" medium="image" fileSize="381492">
        <media:title type="plain">Clinical data illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Pediatric PRVs top the voucher popularity contest</title>
      <description>
        <![CDATA[With three rare pediatric disease priority review vouchers (RPD PRVs) awarded just since the end of March, the nearly year-and-a-half lapse in the program’s reauthorization seems to have had little short-term impact. The three new vouchers bring the total RPD PRVs granted so far this year to seven – one more than the agency issued all last year and down two from the nine given in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730209</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730209-pediatric-prvs-top-the-voucher-popularity-contest</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/Pediatric-exam3.webp?t=1758231919" type="image/jpeg" medium="image" fileSize="423899">
        <media:title type="plain">Pediatric exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Wait almost over, as SBIR nears reauthorization </title>
      <description>
        <![CDATA[A five-year reauthorization of the U.S. Small Business Innovation Research (SBIR) and Small Business Technology Transfer programs is just the president’s signature, or a few days, away.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729828</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729828-wait-almost-over-as-sbir-nears-reauthorization</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/newco-plant-dollar-sign.webp?t=1588285768" type="image/png" medium="image" fileSize="378693">
        <media:title type="plain">Hand holding money plant</media:title>
      </media:content>
    </item>
    <item>
      <title>Compounded weight-loss drugs hit on every side</title>
      <description>
        <![CDATA[True to its word, Novo Nordisk A/S filed a patent infringement lawsuit in U.S. district court against Hims & Hers Health Inc. over compounded versions of Novo’s semaglutide products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728703</guid>
      <pubDate>Mon, 09 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728703-compounded-weight-loss-drugs-hit-on-every-side</link>
    </item>
    <item>
      <title>Unburdening the past, HELPing NIH advance the future</title>
      <description>
        <![CDATA[In keeping with the congressional practice of passing major NIH reform legislation every 10 years, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee took the first step in looking at what can be for the NIH while unburdening it from what has been over the past few years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728648</guid>
      <pubDate>Thu, 05 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728648-unburdening-the-past-helping-nih-advance-the-future</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/NIH-Biomedical-Research-Center.webp?t=1770330404" type="image/jpeg" medium="image" fileSize="1085363">
        <media:title type="plain">NIH Biomedical Research Center</media:title>
        <media:description type="plain">NIH Biomedical Research Center in Baltimore. Credit: NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>Senators, experts agree country of origin not an Rx trade secret</title>
      <description>
        <![CDATA[The days of the U.S. FDA considering as trade secrets country-of-origin info for drugs and their ingredients have to end, the Senate Aging Committee was told at a Jan. 29 hearing on truth in drug labeling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728478</guid>
      <pubDate>Thu, 29 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728478-senators-experts-agree-country-of-origin-not-an-rx-trade-secret</link>
    </item>
    <item>
      <title>Fiscal 2026 HHS spending bill in jeopardy? </title>
      <description>
        <![CDATA[After the U.S. House passed a package of spending bills Jan. 22 to fund several agencies and departments, including Health and Human Services, through fiscal 2026, the Senate was expected to quickly follow suit to ensure that no part of the federal government would shut down when the current continuing resolution expires Jan. 30. That was before a confrontation with Immigration and Customs Enforcement in Minnesota turned deadly over the weekend.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728318</guid>
      <pubDate>Mon, 26 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728318-fiscal-2026-hhs-spending-bill-in-jeopardy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Legislation seeks to guard NIH from politicization</title>
      <description>
        <![CDATA[The U.S. NIH may be weathering the budget storm thanks to bipartisan congressional support, but another squall line is forming on the horizon over politicization of the research agency.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728086</guid>
      <pubDate>Fri, 23 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728086-legislation-seeks-to-guard-nih-from-politicization</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Exterior-of-NIH-Vaccine-Research-Center.webp?t=1746047246" type="image/jpeg" medium="image" fileSize="402922">
        <media:title type="plain">Exterior of NIH Vaccine Research Center</media:title>
        <media:description type="plain">The NIH's Vaccine Research Center in Bethesda, Md. Credit: Grandbrothers - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>NIH spared slash-and-burn in congressional spending agreement </title>
      <description>
        <![CDATA[The good news is that the U.S. Congress is on track to pass a slate of fiscal 2026 spending bills before the current continuing resolution expires Jan. 30. So, barring any last-minute disputes or legislative hostage-taking, there should be no repeat of last year’s 43-day shutdown that impacted NIH grants and activities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728147</guid>
      <pubDate>Wed, 21 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728147-nih-spared-slash-and-burn-in-congressional-spending-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-Capitol-and-100-bills.webp?t=1608670998" type="image/png" medium="image" fileSize="689551">
        <media:title type="plain">U.S. Capitol and $100 bills</media:title>
      </media:content>
    </item>
    <item>
      <title>New legislation would apply product liability principles to AI</title>
      <description>
        <![CDATA[Software as a service has typically been less susceptible to liability than products, but that may soon come to an end if the AI LEAD Act, sponsored by a bipartisan pair of members of the Senate, gains sufficient traction.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727573</guid>
      <pubDate>Tue, 06 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727573-new-legislation-would-apply-product-liability-principles-to-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/washington-dc-1624419.webp?t=1588689744" type="image/png" medium="image" fileSize="640104">
        <media:title type="plain">U.S. Capitol building, Washington D.C.</media:title>
      </media:content>
    </item>
    <item>
      <title>US Senate ends 2025 with no gift for kids with cancer</title>
      <description>
        <![CDATA[After being unanimously passed by the U.S. House Dec. 1, the bipartisan Mikaela Naylon Give Kids a Chance Act seemed to be headed for sure passage in the Senate before it adjourned late last week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727359</guid>
      <pubDate>Tue, 23 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727359-us-senate-ends-2025-with-no-gift-for-kids-with-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-Washington-congress-senate-house.webp?t=1588689130" type="image/png" medium="image" fileSize="1737899">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>US Biosecure Act a vote away from law</title>
      <description>
        <![CDATA[“If at first you don’t succeed, try, try again” seems to be the motto of U.S. lawmakers – at least when it comes to the bipartisan Biosecure Act. After missing a ride last year in the must-pass annual defense spending bill, a version of the bill that seeks to protect the genetic data of Americans while securing U.S. pharmaceutical supply chains made it into the 2026 National Defense Authorization Act, which is now just a Senate vote away from becoming law.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727232</guid>
      <pubDate>Tue, 16 Dec 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727232-us-biosecure-act-a-vote-away-from-law</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-privacy-globe.webp?t=1601416325" type="image/png" medium="image" fileSize="866096">
        <media:title type="plain">Lock on digital globe illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>US Biosecure Act a vote away from law</title>
      <description>
        <![CDATA[“If at first you don’t succeed, try, try again” seems to be the motto of U.S. lawmakers – at least when it comes to the bipartisan Biosecure Act. After missing a ride last year in the must-pass annual defense spending bill, a version of the bill that seeks to protect the genetic data of Americans while securing U.S. pharmaceutical supply chains made it into the 2026 National Defense Authorization Act, which is now just a Senate vote away from becoming law.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726991</guid>
      <pubDate>Mon, 15 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726991-us-biosecure-act-a-vote-away-from-law</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-privacy-globe.webp?t=1601416325" type="image/png" medium="image" fileSize="866096">
        <media:title type="plain">Lock on digital globe illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>US pediatric voucher making moves in Congress</title>
      <description>
        <![CDATA[The next stop on the comeback tour for the U.S. FDA’s Rare Pediatric Disease Priority Review Voucher program is the Senate, after the House unanimously passed the Mikaela Naylon Give Kids a Chance Act, H.R. 1262, Dec. 1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726798</guid>
      <pubDate>Tue, 02 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726798-us-pediatric-voucher-making-moves-in-congress</link>
    </item>
    <item>
      <title>US, European biotechs lead budding organ-on-a-chip market</title>
      <description>
        <![CDATA[U.S. and European organ-on-a-chip specialty biotechnology companies are driving development of organ-on-a-chip technologies, fueled by the U.S. FDA’s decision to phase out animal testing for investigational new drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726519</guid>
      <pubDate>Thu, 20 Nov 2025 07:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726519-us-european-biotechs-lead-budding-organ-on-a-chip-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Emulate-Chip-R1-Brain-19nov25.webp?t=1763590564" type="image/jpeg" medium="image" fileSize="322160">
        <media:title type="plain">Emulate Chip R1 Brain</media:title>
        <media:description type="plain">Emulate Brain-Chip R1 integrates FCDI iCell products co-cultured with Emulate's induced brain microvascular endothelial cells, providing a platform that models the complexities of the human brain. Credit: Emulate</media:description>
      </media:content>
    </item>
    <item>
      <title>US, European biotechs lead budding organ-on-a-chip market</title>
      <description>
        <![CDATA[U.S. and European organ-on-a-chip specialty biotechnology companies are driving development of organ-on-a-chip technologies, fueled by the U.S. FDA’s decision to phase out animal testing for investigational new drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726207</guid>
      <pubDate>Wed, 19 Nov 2025 07:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726207-us-european-biotechs-lead-budding-organ-on-a-chip-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Emulate-Chip-R1-Brain-19nov25.webp?t=1763590564" type="image/jpeg" medium="image" fileSize="322160">
        <media:title type="plain">Emulate Chip R1 Brain</media:title>
        <media:description type="plain">Emulate Brain-Chip R1 integrates FCDI iCell products co-cultured with Emulate's induced brain microvascular endothelial cells, providing a platform that models the complexities of the human brain. Credit: Emulate</media:description>
      </media:content>
    </item>
    <item>
      <title>Amended stopgap spending bill includes full 2026 funding for FDA</title>
      <description>
        <![CDATA[The U.S. House is expected to vote late Nov. 12 on an amended continuing resolution (CR) to end the historic 43-day partial government shutdown. Already passed by the Senate, the CR would fully reopen the government and fund it through Jan. 30. President Donald Trump has said he will sign the CR, which ensures federal employees furloughed during the shutdown will receive back pay and will not be terminated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726124</guid>
      <pubDate>Wed, 12 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726124-amended-stopgap-spending-bill-includes-full-2026-funding-for-fda</link>
    </item>
    <item>
      <title>Rx tariff a stick and a carrot for US price, onshoring deals</title>
      <description>
        <![CDATA[Although U.S. President Donald Trump’s Oct. 1 start date for a hefty biopharma sector tariff has come and gone, the threat remains, serving as both a stick and a carrot to get drug companies to come to the table with their best deals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725001</guid>
      <pubDate>Mon, 13 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725001-rx-tariff-a-stick-and-a-carrot-for-us-price-onshoring-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tariff-trade-illustration.webp?t=1746219221" type="image/jpeg" medium="image" fileSize="370006">
        <media:title type="plain">Digital globe illustrating pharma trade, tariffs</media:title>
      </media:content>
    </item>
    <item>
      <title>US Congress seeks to undo IP damage wrought by Supreme Court</title>
      <description>
        <![CDATA[A yearslong bipartisan effort to end the patent-eligibility chaos the U.S. Supreme Court created more than a decade ago could finally come to fruition with the current Congress.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724976</guid>
      <pubDate>Thu, 09 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724976-us-congress-seeks-to-undo-ip-damage-wrought-by-supreme-court</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/patent-law.webp?t=1588277944" type="image/png" medium="image" fileSize="626639">
        <media:title type="plain">Patent law book and gavel</media:title>
      </media:content>
    </item>
    <item>
      <title>New FDA submissions stalled during US government funding lapse </title>
      <description>
        <![CDATA[Caught between the start of fiscal 2026 and a congressional funding standoff that shut down much of the U.S. federal government Oct. 1, the FDA will not be able to collect 2026 user fees until Congress agrees on a continuing resolution or a 2026 appropriations bill.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724640</guid>
      <pubDate>Wed, 01 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724640-new-fda-submissions-stalled-during-us-government-funding-lapse</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Laptop-displaying-FDA-logo.webp?t=1695241730" type="image/png" medium="image" fileSize="347445">
        <media:title type="plain">Laptop displaying FDA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>HHS rolls the numbers as shutdown looms for US government</title>
      <description>
        <![CDATA[Despite down-to-the-wire negotiations, the odds are that parts of the U.S. government will shut down at midnight Sept. 30, as Senate Democrats refused to support a seven-week, clean continuing resolution already passed by the House to keep the government funded while Congress hammers out fiscal 2026 spending bills.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724623</guid>
      <pubDate>Tue, 30 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724623-hhs-rolls-the-numbers-as-shutdown-looms-for-us-government</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-Capitol-at-night.webp?t=1759269324" type="image/jpeg" medium="image" fileSize="854186">
        <media:title type="plain">US Capitol at night</media:title>
      </media:content>
    </item>
    <item>
      <title>More US federal layoffs, future of SBIR on the table</title>
      <description>
        <![CDATA[The struggle to avoid a partial U.S. government shutdown at midnight Sept. 30 is getting a lot of attention, as the stakes increase every day of the political standoff. Meanwhile, Sept. 30 also could be the end of the 43-year-old Small Business Innovation Research (SBIR) program, which has been a funding boon for biotech and med-tech startups, if Congress can’t come together on a reauthorization bill.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724536</guid>
      <pubDate>Thu, 25 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724536-more-us-federal-layoffs-future-of-sbir-on-the-table</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Hand-holding-a-pink-slip-or-termination-notice-against-a-blurred-office-background.webp?t=1739918614" type="image/jpeg" medium="image" fileSize="97603">
        <media:title type="plain">Hand holding a pink slip or termination notice against a blurred office background</media:title>
      </media:content>
    </item>
    <item>
      <title>House committee advances Medicare breakthrough devices coverage bill</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[A committee of the House of Representatives advanced a bill that if passed will give eligible breakthrough medical devices four years of Medicare coverage.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724132</guid>
      <pubDate>Fri, 19 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724132-house-committee-advances-medicare-breakthrough-devices-coverage-bill</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-health-flag-medicare.webp?t=1629754472" type="image/png" medium="image" fileSize="585251">
        <media:title type="plain">U.S. flag, stethoscope</media:title>
      </media:content>
    </item>
    <item>
      <title>Trying again: Rare pediatric PRV program heads to House</title>
      <description>
        <![CDATA[Renewing hopes of restoring the rare pediatric disease priority review voucher (RPD PRV) program that expired at the end of 2024, the House Energy and Commerce Committee voted 47-0 Sept. 17 to advance the Give Kids a Chance Act of 2025 (H.R. 1262), one of six pieces of legislation slated to move to the full U.S. House for consideration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724312</guid>
      <pubDate>Fri, 19 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724312-trying-again-rare-pediatric-prv-program-heads-to-house</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/Capitol.webp?t=1588711607" type="image/png" medium="image" fileSize="672290">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>OBBBA changes odds for next round of US Rx price negotiations</title>
      <description>
        <![CDATA[Oddsmakers placing their bets on which drugs will be in play for round 3 of the U.S. Inflation Reduction Act (IRA) price negotiations are doing some reshuffling, thanks to an orphan drug provision tucked into the Trump administration’s One Big Beautiful Bill Act (OBBBA) that was signed into law on the Fourth of July.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723802</guid>
      <pubDate>Wed, 03 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723802-obbba-changes-odds-for-next-round-of-us-rx-price-negotiations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Prescription-drug-bottles-and-pills.webp?t=1623264455" type="image/png" medium="image" fileSize="297425">
        <media:title type="plain">Prescription drug bottles and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>PBM practices a threat to future of biosimilars, FTC, DOJ told </title>
      <description>
        <![CDATA[Once again, U.S. legislative reforms to rein in pharmacy benefit manager (PBM) business practices missed a ride to finally becoming law. This time, they were kicked out of the Trump administration’s budget reconciliation bill that was signed into law July 4. House Resolution 1, as first passed in the lower chamber, included a few PBM reforms, but they were deleted from the Senate version that ultimately became law because the parliamentarian ruled they didn’t meet the restrictions placed on reconciliation measures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722139</guid>
      <pubDate>Mon, 14 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722139-pbm-practices-a-threat-to-future-of-biosimilars-ftc-doj-told</link>
    </item>
    <item>
      <title>Industry could feel fallout of Pfizer vaccine scrutiny</title>
      <description>
        <![CDATA[In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative steps Congress may take in response to allegations that Pfizer slow-walked its COVID-19 vaccine development in 2020 so the trial results wouldn’t have to be disclosed until after the presidential election.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721905</guid>
      <pubDate>Thu, 03 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721905-industry-could-feel-fallout-of-pfizer-vaccine-scrutiny</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-vials1.webp?t=1619812051" type="image/png" medium="image" fileSize="611753">
        <media:title type="plain">Drug vials</media:title>
      </media:content>
    </item>
    <item>
      <title>Industry could feel fallout of Pfizer vaccine scrutiny</title>
      <description>
        <![CDATA[In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative steps Congress may take in response to allegations that Pfizer slow-walked its COVID-19 vaccine development in 2020 so the trial results wouldn’t have to be disclosed until after the presidential election.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721684</guid>
      <pubDate>Wed, 02 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721684-industry-could-feel-fallout-of-pfizer-vaccine-scrutiny</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-vials1.webp?t=1619812051" type="image/png" medium="image" fileSize="611753">
        <media:title type="plain">Drug vials</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA scrutinizing trials sending US patient cells to China</title>
      <description>
        <![CDATA[Using informed consent to do what Congress couldn’t, the U.S. FDA is flexing its regulatory authority to halt clinical trials that involve sending cells from American patients to China or other adversarial nations for genetic engineering and subsequent infusion back into the patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721534</guid>
      <pubDate>Tue, 24 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721534-fda-scrutinizing-trials-sending-us-patient-cells-to-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons2.webp?t=1601583324" type="image/png" medium="image" fileSize="431526">
        <media:title type="plain">FDA icons </media:title>
      </media:content>
    </item>
    <item>
      <title>FDA scrutinizing trials sending US patient cells to China</title>
      <description>
        <![CDATA[Using informed consent to do what Congress couldn’t, the U.S. FDA is flexing its regulatory authority to halt clinical trials that involve sending cells from American patients to China or other adversarial nations for genetic engineering and subsequent infusion back into the patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721434</guid>
      <pubDate>Fri, 20 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721434-fda-scrutinizing-trials-sending-us-patient-cells-to-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons2.webp?t=1601583324" type="image/png" medium="image" fileSize="431526">
        <media:title type="plain">FDA icons </media:title>
      </media:content>
    </item>
  </channel>
</rss>
